Targeting Xist with compounds that disrupt RNA structure and X inactivation

Rodrigo Aguilar, Kerrie B. Spencer, Barry Kesner, Noreen F. Rizvi, Maulik D. Badmalia, Tyler Mrozowich, Jonathan D. Mortison, Carlos Rivera, Graham F. Smith, Julja Burchard, Peter J. Dandliker, Trushar R. Patel, Elliott B. Nickbarg and Jeannie T. Lee ()
Additional contact information
Rodrigo Aguilar: Massachusetts General Hospital
Kerrie B. Spencer: Merck & Co.
Barry Kesner: Massachusetts General Hospital
Noreen F. Rizvi: Merck & Co.
Maulik D. Badmalia: University of Lethbridge
Tyler Mrozowich: University of Lethbridge
Jonathan D. Mortison: Merck & Co.
Carlos Rivera: Massachusetts General Hospital
Graham F. Smith: Merck & Co.
Julja Burchard: Merck & Co.
Peter J. Dandliker: Merck & Co.
Trushar R. Patel: University of Lethbridge
Elliott B. Nickbarg: Merck & Co.
Jeannie T. Lee: Massachusetts General Hospital

Nature, 2022, vol. 604, issue 7904, 160-166

Abstract: Abstract Although more than 98% of the human genome is non-coding1, nearly all of the drugs on the market target one of about 700 disease-related proteins. The historical reluctance to invest in non-coding RNA stems partly from requirements for drug targets to adopt a single stable conformation2. Most RNAs can adopt several conformations of similar stabilities. RNA structures also remain challenging to determine3. Nonetheless, an increasing number of diseases are now being attributed to non-coding RNA4 and the ability to target them would vastly expand the chemical space for drug development. Here we devise a screening strategy and identify small molecules that bind the non-coding RNA prototype Xist5. The X1 compound has drug-like properties and binds specifically the RepA motif6 of Xist in vitro and in vivo. Small-angle X-ray scattering analysis reveals that RepA can adopt multiple conformations but favours one structure in solution. X1 binding reduces the conformational space of RepA, displaces cognate interacting protein factors (PRC2 and SPEN), suppresses histone H3K27 trimethylation, and blocks initiation of X-chromosome inactivation. X1 inhibits cell differentiation and growth in a female-specific manner. Thus, RNA can be systematically targeted by drug-like compounds that disrupt RNA structure and epigenetic function.

Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41586-022-04537-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:604:y:2022:i:7904:d:10.1038_s41586-022-04537-z

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-022-04537-z

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().